Text mining is beginning to establish its place across the life sciences industry as a way for researchers to quickly analyze massive amounts of literature, as well as conference abstracts, patents and clinical data to help inform and guide R&D.
From drug discovery and clinical trial development to drug safety monitoring and competitive intelligence, text mining has many applications for life science companies. At Boehringer Ingelheim Pharmaceuticals Jon Hill, Principal Scientist in Computational Biology, has diligently explored how text mining works in practice.
For a recent webinar program with CCC’s Chris Kennneally, the Connecticut-based Hill discussed the application, outcomes and business value of text mining; its impact on early drug discovery; and what the future may hold. He shared insights on the various sources of text-based data as well as the impact of mixing data types.
Podcast: Play in new window | Download | Embed